Brief: CASI Pharmaceuticals Announces CNCT19 (CD19 Car-T) Granted Orphan Drug Designation By The U.S. FDA
18/01/2022 14:20
Jan 18 (Reuters) - CASI Pharmaceuticals Inc CASI.O :
* CASI PHARMACEUTICALS ANNOUNCES CNCT19 (CD19 CAR-T) GRANTED
ORPHAN DRUG DESIGNATION BY THE U.S. FDA
Source text for Eikon: ID:nPnbNCjNca
Further company coverage: CASI.O
Recent news on CASI Pharmaceuticals
See all newsBrief: Casi Pharmaceuticals Reports The Receipt Of Drug Registration Certificate For Thiotepa In China
CASI Pharmaceuticals Q3 revenue drops 60%, net loss widens
Brief: CASI Pharmaceuticals Inc Reports The Expiration Of Import Drug Registration License For Folotyn® In China
Casi Pharmaceuticals Inc Expected To Post A Loss Of 47 Cents A Share: Earnings Preview
Casi Pharmaceuticals Inc Reports Results For The Quarter Ended March 31: Earnings Summary